Recent Company News

• 07:09 PM ET Jun 01, 2026
  

  Ono Pharmaceutical presents new data from phase 2 clinical study of ONO-4578 at ASCC 2026 (¥2322.0000, 0)

• 06:58 AM ET Jun 01, 2026
  

  Bristol Myers Squibb announces Opdivo (nivolumab) in combination with AVD receives expanded EU label with approval in frontline advanced classical Hodgkin lymphoma ($57.18, 0.00)

• 05:09 PM ET May 31, 2026
  

  Pfizer reports detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 BREAKWATER trial ($26.18, 0.00)

• 07:07 PM ET May 27, 2026
  

  Ono Pharmaceutical to presents new clinical data from phase 2 study of ONO-2808 at World Parkinson Congress (¥2367.0000, 0)

• 09:02 AM ET May 26, 2026
  

  Pfizer Canada announces that BRAFTOVI (encorafenib) will be funded under Ontario's Funding Accelerated for Specific Treatments (FAST) program ($25.90, 0.00)

• 08:10 AM ET May 22, 2026
  

  EU's CHMP adopted a positive opinion recommending a change to the terms of the marketing authorisation for Braftovi

• 08:41 PM ET May 05, 2026
  

  NICE recommends Pfizer's Braftovi plus Mektovi to treat BRAF V600E mutation-positive advanced NSCLC ($26.45, 0.00)

• 05:21 PM ET Apr 28, 2026
  

  NICE recommends ripretinib (Qinlock) for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors in adults

• 06:20 AM ET Apr 24, 2026
  

  EU's CHMP adopted a positive opinion recommending change to the terms of the marketing authorisation for Opdivo ($59.02, 0.00)

• 04:59 PM ET Apr 22, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market